My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Genome Med. 2009 Dec 9;1(12):114.

    Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases.

    Nathan DG, Orkin SH.

    Source

    Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

    Abstract

    The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions.

    PMID:
    20017892
    [PubMed]
    PMCID: PMC2808730
    Free PMC Article

    LinkOut - more resources

    Full Text Sources

    Medical

    Libraries

      Supplemental Content

      Click here to read Click here to read

      Related citations

      See reviews... See all...

      Related information

      • Related Citations
        Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
      • References for this PMC Article
        Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
      • Free in PMC
        Free full text articles in PMC

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk